Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ALLK

ALLK - Allakos Inc Stock Price, Fair Value and News

$0.33 
Market Closed

Price Targets

ALLK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALLK Price Action

Last 30 days

3.1%

Last 90 days

22.2%

Trailing 12 Months

-74.4%

ALLK RSI Chart

ALLK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALLK Valuation

Market Cap

29.8M

Price/Earnings (Trailing)

-0.42

EV/EBITDA

-0.08

Price/Free Cashflow

-0.33

MarketCap/EBT

-0.35

ALLK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ALLK Fundamentals

ALLK Earnings

Earnings (TTM)

-70.9M

ALLK Profitability

Return on Equity

-127.75%

Return on Assets

-118.99%

Free Cashflow Yield

-300.64%

ALLK Investor Care

Shares Dilution (1Y)

2.07%

About Allakos Inc

ALLK
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.
 CEO
 WEBSITEallakos.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES123

Allakos Inc Frequently Asked Questions

ALLK is the stock ticker symbol of Allakos Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu May 15 2025, market cap of Allakos Inc is 29.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ALLK's fair value in chart for subscribers.

The fair value guage provides a quick view whether ALLK is over valued or under valued. Whether Allakos Inc is cheap or expensive depends on the assumptions which impact Allakos Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLK.